Based on a cohort of 48 stage I-II colon cancer patients, we set out to characterize consistent expression differences in sRNAs between cancer and normal tissue, and between colon cancer subtypes characterized by MSI status, BRAF and KRAS mutations, and tumor location (Additional file 1: Table S1). This evidence concerns the gene KRAS and malignant colon neoplasm.